NEoadjuvant Total RX for Borderline Unresectable Esophageal Squamous Cell Carcinoma: a Prospective Randomized, Three-Arm, Open-Label Phase II Trial (NEXUS-2)
Latest Information Update: 31 Dec 2024
At a glance
- Drugs Tislelizumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer; Thoracic neoplasms
- Focus Therapeutic Use
- Acronyms NEXUS-2
Most Recent Events
- 30 May 2024 New trial record